Acasti Pharma (NASDAQ:ACST) Share Price Crosses Above Two Hundred Day Moving Average of $2.75

Acasti Pharma Inc. (NASDAQ:ACST) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.75 and traded as high as $3.08. Acasti Pharma shares last traded at $2.96, with a volume of 13,180 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Craig Hallum began coverage on Acasti Pharma in a research report on Wednesday, February 7th. They issued a “buy” rating and a $6.00 price target for the company.

Acasti Pharma Trading Down 2.3 %

The stock has a market capitalization of $27.82 million, a PE ratio of -0.58 and a beta of 1.55. The firm has a 50-day moving average price of $3.28 and a 200-day moving average price of $2.75.

Acasti Pharma (NASDAQ:ACST) last posted its quarterly earnings data on Monday, February 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.02. Sell-side analysts expect that Acasti Pharma Inc. will post -1.44 earnings per share for the current fiscal year.

About Acasti Pharma

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.